Search

Your search keyword '"So, D."' showing total 77,216 results

Search Constraints

Start Over You searched for: Author "So, D." Remove constraint Author: "So, D." Journal blood Remove constraint Journal: blood
77,216 results on '"So, D."'

Search Results

1. Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: A Report from the Children's Oncology Group

2. Whole-genome analysis of plasma fibrinogen reveals population-differentiated genetic regulators with putative liver roles

3. Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

4. HA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation

5. Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)

6. Wiskott-Aldrich syndrome: a study of 577 patients defines the genotype as a biomarker for disease severity and survival

7. A genetic association study of circulating coagulation factor VIII and von Willebrand factor levels

9. Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis

10. Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations

11. Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia

16. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

20. Use of HSC-targeted LNP to generate a mouse model of lethal α-thalassemia and treatment via lentiviral gene therapy

21. KDM6A regulates immune response genes in multiple myeloma

22. Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD

24. Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome

25. Prevalence and significance of DDX41 gene variants in the general population

28. Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML

31. NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome

34. Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma

36. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

37. Antibody-mediated antigen loss switches augmented immunity to antibody-mediated immunosuppression

38. Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

39. An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

42. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

44. Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens

46. Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML

47. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population

49. Differential diagnosis of bone marrow failure syndromes guided by machine learning

50. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma

Catalog

Books, media, physical & digital resources